Monitoring Treatment for Metastatic Kidney Cancer
TDM for Optimized Outcome in Patients With mRCC.
Recruiting
Observational Study
Kidney Cancer
Renal Cell Carcinoma Metastatic
Drug Toxicity
Drug Side Effect
Drug Mechanism
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 200 (estimated)
- Sponsor
- Niels Fristrup · Other
Who this trial is looking for
This trial is looking for patients in Denmark who are being treated for metastatic renal cell carcinoma. Participants will help researchers understand how monitoring drug levels can affect treatment outcomes and side effects.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with metastatic renal cell carcinoma.
- I am receiving medical treatment for my kidney cancer.
You may not be able to join if
- I have not provided written informed consent.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this observational study is to assess the role of plasma concentration monitoring of treatment drugs for patients with metastatic renal cell carcinoma (mRCC) in terms of efficacy and side effects. It furthermore holds microbiome characterization of CPI-treated patients.
Furthermore, the investigators examines the role of anti-drug antibodies and receptor polymorphisms in CTLA-4 and…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients in Denmark with medically treated metastatic renal cell carcinoma.
Exclusion Criteria:
* No written informed consent.
Contacts